Compare BioNano Genomics Inc (BNGO) vs First Citizens BancShares Inc (FCNCA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs First Citizens BancShares Inc — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.77M), while First Citizens BancShares Inc trades at $2,270.44 (market cap $25.26B). The key difference: First Citizens BancShares Inc is far larger — about 1834.4× BioNano Genomics Inc's market cap, and First Citizens BancShares Inc pays a 0.37% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | FCNCA | |
|---|---|---|
Market Cap | $13.77M | $25.26B |
Sector | Health | Sector/Thematic |
52-Week High | $4.92 | $2.27K |
52-Week Low | $1.06 | $1.64K |
Enterprise Value | $16.38M | — |
Dividend Yield | — | 0.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.18, down 0.84% today, with a bullish technical signal from moving averages but a neutral stance from oscillators. The company shows improving financial trends, with net losses narrowing significantly from -$232M in 2023 to -$26M in 2025, and recent earnings beats. Revenue remains steady around $29M, while analyst sentiment is positive with 57% buy ratings.
Outlook: BNGO presents a speculative opportunity with strong analyst support and improving fundamentals, but risks include persistent negative cash flows, high operating costs, and competitive pressures in genomics. The stock's low valuation multiples may attract value investors, yet profitability remains a key hurdle.
First Citizens BancShares (FCNCA) trades at $2,271.31, up 0.81% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with a 12.19 P/E ratio, 25.23% net income margin, and consistent earnings beats in recent quarters. Recent business developments include expansion of commercial lending operations and strategic real estate acquisitions, supporting growth initiatives.
FCNCA presents a mixed outlook with strong earnings performance and reasonable valuation offset by cautious analyst sentiment. While technical indicators suggest continued upside potential, the 81.82% hold rating from analysts indicates concerns about valuation and deposit risks. Key opportunities include expanding commercial banking services, while risks center on net interest margin pressure and elevated uninsured deposits at 38.3%.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About First Citizens BancShares Inc
First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →
